Locanabio to Present at 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that Jim Burns, PhD, chief executive officer, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:30 a.m. ET. Dr. Burns will provide an overview of the company’s proprietary RNA targeting CORRECTx™ platform and an update on recent program developments and company operations.

A live webcast will be available on the Events & Presentations section of the company’s website at https://locanabio.com/news/#events. The webcast will be available for 90 days following the presentation.

About Locanabio, Inc.
Locanabio is a leader in developing a new class of genetic medicines that has the potential to significantly improve the lives of patients with devastating genetic diseases by correcting the message of disease-causing RNA. Our proprietary platform, CORRECTx™, uses gene therapy to deliver RNA-binding protein systems that can be engineered to selectively manipulate disease-causing RNA by multiple mechanisms. Our systems are designed to provide a durable therapy with a single administration without altering a cell’s DNA. Locanabio’s CORRECTx platform has applications across a range of tissues and diseases and we are currently advancing programs in neurodegenerative, neuromuscular and retinal diseases. For more information, visit www.locanabio.com.

Media Contact
Jenna Urban
Berry & Company
jurban@berrypr.com
+1-212-253-8881

View original content:https://www.prnewswire.com/news-releases/locanabio-to-present-at-40th-annual-jp-morgan-healthcare-conference-301453289.html

SOURCE Locanabio, Inc.